Podcasts / Epilepsy & Driving – Navigating the Grey Areas – Lecture
Save
0.5 hours
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.
0 hours
These are activities that require reflection on feedback about your work.
0 hours
These are activities that use your work data to ensure quality results.
Educational Activities (EA)
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.
Reviewing Performance (RP)
These are activities that require reflection on feedback about your work.
Measuring Outcomes (MO)
These are activities that use your work data to ensure quality results.
70% of GPs rated this lecture as excellent
In this Healthed lecture, Professor Ernest Somerville explains that there still exist a number of grey areas – grey areas that can be challenging, complicated or just confusing. Professor Somerville will detail some of these difficult areas and provide practical advice on issues such as where there’s a history of provoked seizures (as opposed to unprovoked seizures), the different rules for commercial vs private licences, dealing with unreliable patients and patients who pressure the doctor to claim they are fit to drive when their history would suggest otherwise.
Multiple Sclerosis vs Antibody Disease – What GPs Need to Know
Using SGLT2 to Reduce Cardiovascular Death in T2D – Important Updates for GPs
Menopause and MHT: Maximising Benefits & Minimising Risks
Peripheral Arterial Disease
expert
Neurologist; Director, Comprehensive Epilepsy Service, Prince of Wales Hospital, Sydney; Conjoint Professor, University of New South Wales; Chair, Driving Committees of ANZAN and the ESA
Browse the latest podcasts from Healthed.
You have completed the Educational Activities (EA) component of this activity.
Select ‘Confirm & claim CPD‘ to confirm you have engaged with this activity in its entirety and claim your CPD.
You will be taken to explore further CPD learning available to you.
Menopause and MHT
Multiple sclerosis vs antibody disease
Using SGLT2 to reduce cardiovascular death in T2D
Peripheral arterial disease